avb-s6-500
mAbexperimental
Clinical trial activity
10 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
7
Phase 3
1
Phase 4
0
Earliest trial started Jan 31, 2018 (NCT03401528)
Timeline
Indications
Studied for
- Carcinoma, Ovarian Epithelial · Phase 1
- Carcinoma, Renal Cell · Phase 1/Phase 2
- Carcinoma, Transitional Cell · Phase 2
- Fallopian Tube Neoplasms · Phase 1/Phase 2
- Glomerulonephritis, IGA · Phase 2
- Hamartoma · Phase 1/Phase 2
- Healthy Volunteers · Phase 1
- Ovarian Neoplasms · Phase 3
- Pancreatic Neoplasms · Phase 1/Phase 2
- Uterine Neoplasms · Phase 1
Mechanism of action
- Growth arrest-specific protein 6INHIBITOR
Growth arrest-specific protein 6 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594462 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05826015 | Phase 1 | Dec 31, 2023 | Aravive Biologics, National Cancer Institute (NCI), Washington University in St. Louis |
| NCT04983407 | Phase 1/Phase 2 (Phase 2) | Jul 28, 2021 | Aravive Biologics |
| NCT04729608 | Phase 3 | Apr 22, 2021 | Aravive Biologics, European Network for Gynaecological Oncological Trial, GOG Foundation, Inc. |
| NCT04300140 | Phase 1/Phase 2 (Phase 2) | Mar 31, 2020 | Aravive Biologics |
| NCT04042623 | Phase 2 | Nov 30, 2019 | Aravive Biologics |
| NCT04019288 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2019 | Aravive Biologics, AstraZeneca, University of Texas at Houston |
| NCT04004442 | Phase 2 | Sep 30, 2019 | Aravive Biologics, Merck Serono, University of Oklahoma |
| NCT03639246 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2018 | Aravive Biologics |
| NCT03607955 | Phase 1 | Oct 31, 2018 | Aravive Biologics, Washington University in St. Louis |
| NCT03401528 | Phase 1 | Jan 31, 2018 | Aravive Biologics, Orlando Clinical Research Center |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aravive Biologics | For profit | 10 | 6 | 3 | 2018 |
| Washington University in St. Louis | Academic/Hospital | 2 | 2 | 1 | 2018 |
| AstraZeneca | For profit | 1 | 0 | 1 | 2019 |
| European Network for Gynaecological Oncological Trial | Academic/Hospital | 1 | 0 | 1 | 2021 |
| GOG Foundation, Inc. | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Merck Serono | For profit | 1 | 0 | 1 | 2019 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2023 |
| Orlando Clinical Research Center | For profit | 1 | 0 | 1 | 2018 |
| University of Oklahoma | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2019 |
10 organizations
Page 1 / 1